FTC slams PBMs for boosting specialty drug prices at the expense of the U.S. health care system

PBMs are ‘charging enormous markups on dozens of lifesaving drugs,’ an agency official said.

For the second time in less than a year, the Federal Trade Commission released a highly critical report of pharmacy benefit managers, which play a crucial but opaque role in the pharmaceutical supply chain. And the findings may provide further impetus for legislative action to curb practices that critics say contribute to the rising cost of prescription drugs.

Read the full story >